Human Milk Fortification With Adjustable Versus Targeted Method (FAT)

November 27, 2023 updated by: University of Calgary

Effect of Adjustable Versus Targeted Human Milk Fortification on Weight Gain in Preterm Infants With Birth Weight <1250 g: A Randomized Controlled Trial

Research question: Do preterm infants born <1250 g achieve better weight gain with targeted fortification compared with the adjustable fortification of human milk?

Hypothesis: Targeted fortification of human milk results in better weight gain in infants with birth weight <1250 gr when compared to the adjustable fortification.

Study design: Open-label, pragmatic, parallel randomized controlled trial in appropriate for gestational age infants with birth weight <1250 g.

Study Overview

Detailed Description

Human milk is the ideal diet for neonates. However, it does not provide enough energy, protein, and sodium to meet the nutritional requirements of very preterm infants. Postnatal growth failure is common despite the current use of human milk fortifiers. The main human milk fortification methods include:

  1. standard HM fortification (SF) which assumes an average composition of breast milk and adds fortifiers in a fixed dosage. It does not account for variations of nutrient content in human milk
  2. Individualized human milk fortification which encompasses two methods:

    1. Adjustable HM fortification (AF): Protein supplementation is provided in addition to SF according to blood urea nitrogen (BUN) concentration which reflects the infant's metabolic response to protein intake. However, there are clinical scenarios in which the BUN levels are not a reliable marker of protein intake, such as acute kidney injury.
    2. Targeted HM fortification (TF): Based on routine analyses of HM that are used to adjust fortification to meet the recommended requirements for infants. It does not take into consideration that the requirements of infants may vary.

SF has frequently failed to achieve appropriate weight gain, while individualized (AF or TF) fortification seems to have better performance. However, the evidence to support one method over the other is lacking.

The objective of the study is to compare weekly average weight gain between preterm infants on AF versus TF.

Once the written consent is obtained, the infant will be randomized to AF or TF. The sequence code will be kept in sequential numbered sealed envelopes. Infants from multiple births will be included as 1 unit and randomized to the same arm of the study.

For patients allocated to the TF group, breast milk will be analyzed twice weekly for energy, protein, and sodium contents. The daily protein, fat, and sodium intakes will be then calculated and optimized to meet the recommended dietary reference intake (DRI) for preterm infants with birth weight <1250 g.

For patients allocated to the AF group, weekly BUN measurements will be performed. Based on BUN concentrations, the liquid protein will be added to achieve the targeted BUN level. Additional calories will be added using formula if growth is suboptimal or DRI is not met based on the assumed human milk content for protein and energy.

The intervention will last 4-8 weeks. For all patients, the day the first BUN concentration and milk analyses are done will be day 1 of intervention. The following measurements will be performed on days 7-8, 14-16, 21-23, and 28-30 of intervention: Weight (grams), length and head circumference (centimeters), BUN and sodium concentrations.

Data on maternal and neonatal characteristics will be collected from their electronic and physical charts.

Study Type

Interventional

Enrollment (Estimated)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Alberta
      • Calgary, Alberta, Canada, T2N2T9
        • Recruiting
        • Foothills Medical Centre
        • Contact:
          • Belal Alshaikh, MD
        • Principal Investigator:
          • Belal Alshaikh, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Infants with birth weight <1250 g born at Foothills Medical Centre.
  • Appropriate for gestational age (AGA) (according to Fenton's Charts).

Exclusion Criteria:

  • Abnormal Newborn Metabolic Screen
  • Major congenital anomalies intervention.
  • Patients who develop NEC prior to enrollment.
  • Patients with confirmed congenital Toxoplasmosis, Syphilis, Rubella, Cytomegalovirus, Herpes simplex virus, Varicella and/or Zika (TORCH infections).
  • Patients receiving systemic steroids.
  • Patients with acute kidney injury (AKI).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Adjustable Human Milk Fortification
Human milk fortification based on blood urea levels

BUN and sodium concentrations will be measured every week in infants on full enteral feeds with fortified human milk.

Liquid protein will be added based on serum urea.

Experimental: Targeted Human Milk Fortification
Human milk fortification based on milk analysis

Human milk will be analyzed twice weekly. Before the day of analysis, each mother will store fresh milk pumped from 10:00 AM until 8:00 AM of the previous day in a refrigerator and bring it to the hospital.

Protein, fat, and sodium supplementation will be added to the human milk to meet the recommended daily intakes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Average weight gain in infants on Adjustable versus Targeted human milk fortification
Time Frame: Weekly for 8 weeks
Average weight gain measured as g/kg per day
Weekly for 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anthropometrics in infants on Adjustable versus Targeted human milk fortification
Time Frame: Weekly for 8 weeks
Measurement of head circumference and length in centimeters.
Weekly for 8 weeks
BUN concentration in infants on Adjustable versus Targeted human milk fortification
Time Frame: Weekly for 4 weeks
mmol/L
Weekly for 4 weeks
Incidence of extra uterine growth restriction
Time Frame: At 36 weeks CA
Defined as weight less than 10th percentile at 36 weeks corrected age (CA)
At 36 weeks CA

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Belal Alshaikh, MD, MSc, University of Calgary

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 10, 2023

Primary Completion (Estimated)

May 31, 2024

Study Completion (Estimated)

May 31, 2025

Study Registration Dates

First Submitted

March 18, 2021

First Submitted That Met QC Criteria

March 18, 2021

First Posted (Actual)

March 22, 2021

Study Record Updates

Last Update Posted (Actual)

November 30, 2023

Last Update Submitted That Met QC Criteria

November 27, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • REB20-2139

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Growth Failure

Clinical Trials on Adjustable Human Milk Fortification

3
Subscribe